Data as of Apr 17
| -0.02 / -0.46%|
Enzo Biochem, Inc. is an integrated life sciences and biotechnology company, which is focused on harnessing biological processes to develop research tools, diagnostics and therapeutics. It also provides test services, including esoteric tests to the medical community. The company operates through three segments: Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. The Enzo Clinical Labs segment is a regional clinical laboratory serving the New York, New Jersey and Eastern Pennsylvania medical communities. This segment offers clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. The Enzo Life Sciences segment manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide and has amassed a large patent and technology portfolio. Its portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides life science researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. The Enzo Therapeutics segment is a biopharmaceutical venture that develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It focuses its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.
|Elazar Rabbani||Chairman, Chief Executive Officer & Secretary|
|Barry W. Weiner||President, CFO, Treasurer, Director & CAO|
|David C. Goldberg||Vice President-Corporate Development|
|Herbert B. Bass||Vice President-Finance|
|Andrew R. Crescenzo||Senior Vice President-Finance|